Is There Opportunity in Personalized Medicine?
Although we're in the early innings of the personal-medication revolution, the stock prices of most biotech companies are sky-high.
The Human Genome Project was declared complete in April 2003 and, while genomic mapping might not explain your fondness for yodeling, it may help cure you of any number of really awful diseases. But does the personalized-medicine revolution present opportunity to investors today?
Personalized medicine is the ability to match the right medicine at the right dose for your particular genetic set. The Human Genome Project, an international effort to sequence and map all the genes of our species, was the first step in personalized medicine. It took about 13 years and $3 billion to map one full genome--the order of the 3 billion or so molecules that make up a human's DNA.
John Waggoner does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.